Stivarga (regorafenib) — United Healthcare
Uterine Sarcoma
Initial criteria
- Diagnosis of uterine sarcoma
- Disease is one of the following: Advanced OR Recurrent/metastatic OR Inoperable
- Used as second-line or subsequent therapy
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Stivarga therapy
Approval duration
12 months